At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...

The financing will in part support development of the firm's PI3K inhibitor paxalisib in PIK3CA-mutated brain cancer and HER2-positive breast cancer.

This month, the firm also performed a 1-for-15 reverse share split to maintain compliance with Nasdaq listing requirements.

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Sanofi will acquire rights to develop and commercialize the drug for $130 million upfront, with Visirna eligible for up to $265 million in milestone payments.

The therapies, which are just starting to enter clinical trials, will need to prove clear clinical and quality-of-life ...

Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

Despite regulatory setbacks, the petitioners believe that survival and other data they've collected themselves are worth ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

The platform will support Anocca's Phase I/II trial of its therapies under development for treating KRAS-mutated pancreatic cancer.

BE-101 is an engineered B-cell therapy, in which a functional copy of the FIX gene is inserted into patients' own B cells in vivo.

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.